Palisade Bio, Inc. (PALI): Cash & Equivalents
$133.38M
As of 2025-12-31
$125.17M
As of 2026-06-30
+120.8%
3-year compound annual growth
n/m
5-year compound annual growth
+39.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $133.38M | n/m | 2026-03-20, Balance as of period end |
| 2024-12-31 | $9.82M | -21.0% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $12.43M | +0.4% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $12.38M | +18.0% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $10.49M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | $713.0K | -86.1% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $5.11M | -11.6% | 2021-03-22, Balance as of period end |
| 2018-12-31 | $5.79M | -13.3% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $6.67M | -56.1% | 2019-03-22, Balance as of period end |
| 2016-12-31 | $15.19M | +222.2% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $4.72M | -62.3% | 2017-03-23, Balance as of period end |
| 2014-12-31 | $12.52M | -25.7% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $16.85M | +126.3% | 2016-03-14, Balance as of period end |
| 2012-12-31 | $7.44M | +216.5% | 2015-03-16, Balance as of period end |
| 2011-12-31 | $2.35M | -74.6% | 2014-03-10, Balance as of period end |
| 2010-12-31 | $9.26M | +301.0% | 2012-03-30, Balance as of period end |
| 2009-12-31 | $2.31M | n/a | 2012-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $133.38M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare PALI, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗